Literature DB >> 9786471

Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.

H Hanaki1, H Labischinski, Y Inaba, N Kondo, H Murakami, K Hiramatsu.   

Abstract

The peptidoglycan compositions of vancomycin-resistant Staphylococcus aureus (VRSA) strain Mu50 (MIC 8 mg/L) and hetero-VRSA strain Mu3 (MIC 3 mg/L) were compared in order to understand the mechanism of vancomycin resistance. As compared with Mu3, the cell wall of Mu50 had increased amounts of glutamine-non-amidated muropeptides and decreased cross-linking of peptidoglycan with a greatly decreased dimer/monomer ratio of muropeptides. In agreement with this observation, the peptidoglycan of Mu50 bound 1.4 times more vancomycin than that of Mu3. The increase in non-amidated muropeptides and the reduced cross-linking of the cell-wall peptidoglycan may contribute to the vancomycin resistance by increasing the consumption of vancomycin by the pre-existing cell wall of Mu50 and reducing the amount of vancomycin reaching the cytoplasmic membrane where the vital targets of the antibiotic are situated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786471     DOI: 10.1093/jac/42.3.315

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  46 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus.

Authors:  H Maki; K Miura; Y Yamano
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 3.  Antimicrobial resistance: the example of Staphylococcus aureus.

Authors:  Franklin D Lowy
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

4.  Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains.

Authors:  Arunachalam Muthaiyan; Radheshyam K Jayaswal; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

5.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.

Authors:  R F Pfeltz; V K Singh; J L Schmidt; M A Batten; C S Baranyk; M J Nadakavukaren; R K Jayaswal; B J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

7.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

8.  Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Akira Iwamoto; Jian-Qi Lian; Hui-min Neoh; Toshiki Maruyama; Yataro Horikawa; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

9.  Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant.

Authors:  Hitoshi Komatsuzawa; Kouji Ohta; Sakuo Yamada; Kerstin Ehlert; Harald Labischinski; Junko Kajimura; Tamaki Fujiwara; Motoyuki Sugai
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

10.  The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes.

Authors:  A Peschel; C Vuong; M Otto; F Götz
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.